Cuifang Cai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cuifang Cai has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Xing Tang
Shenyang Pharmaceutical University
4 shared publications - Haibing He
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
2 shared publications Chaoqun Yu
Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
1 shared publicationFang Li
Department of Pharmaceutics, Shenyang Pharmaceutical University
1 shared publicationGuofei Li
School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China
1 shared publication- Haoyu Gong
Department of Pharmaceutics, College of Pharmacy, Shenyang Pharmaceutical University, Shenyang 10016, Liaoning, PR China
1 shared publication
Latest Publications
- 1 November 2016
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 147, 360-367
Effects of Pluronic F127-PEG multi-gel-core on the release profile and pharmacodynamics of Exenatide loaded in PLGA microspheres
- 1 November 2016
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 147, 360-367
Effects of Pluronic F127-PEG multi-gel-core on the release profile and pharmacodynamics of Exenatide loaded in PLGA microspheres
- 22 January 2014
- Published by Wiley in European Journal of Lipid Science and Technology
- Vol. 116 (4) , 486-496
Preformulation and development of chemically stable lipid emulsions containing a novel taxane derivative, TM‐2
TM‐2 is a novel taxane derivative. The present paper describes an investigation of the physicochemical properties and degradation kinetics of TM‐2 to determine the use of lipid emulsions as suitable drug carriers, and also to develop and evaluate a highly stable and sterile optimal formulation of a TM‐2 lipid emulsion (TLE). The properties of TM‐2, such as its solubility in water and oils, partition coefficient, stability in aqueous solutions and oils, indicated that TM‐2 was an excellent candidate for o/w emulsions. A preformulation study indicated that degradation of TM‐2 took place mostly in water compared with that in oils. Moreover, the influence of pH, temperature, and ionic strength on the stability of TM‐2 in water solutions was assessed. An emulsion formulation of TM‐2 which was stable enough to undergo sterilization was successfully developed. Using the Arrhenius equation, the shelf‐life of TM‐2 in lipid emulsion was estimated to be 2665.5 days at 4°C, which was much longer than that of 113.0 days in aqueous solution. Thus, TLE was clearly superior to the TM‐2 aqueous solution in terms of stability. Short‐term stability investigations showed that the TLE was stable for a period of 3 months at 4 and 25°C.Practical applications: The application of taxanes in anti‐cancer field is limited by de novo refractoriness or acquired resistance, which are common drawbacks to most anti‐cancer cytotoxic agents. TM‐2 is a novel semi‐synthetic taxane derivative, which can overcome multidrug resistance. Some non‐ionic surfactants, such as Cremophor EL and Tween 80 (polysorbate 80), usually used in the commercial formulations of the taxanes to improve their poor water‐solubility, have exhibited serious adverse effects including hypersensitivity reactions and peripheral neuropathy in human. In this study, preformulation study showed that TM‐2 exhibited excellent solubility in oils and, thus, the problems associated with the poor solubility of TM‐2 were overcome by loading TM‐2 into the interior oil phase of o/w lipid emulsions. According to the degradation kinetics results, the shelf lives (T0.9) of TM‐2 lipid emulsions at 25 and 4°C were dramatically prolonged.
- 22 January 2014
- Published by Wiley in European Journal of Lipid Science and Technology
- Vol. 116 (4) , 486-496
Preformulation and development of chemically stable lipid emulsions containing a novel taxane derivative, TM‐2
TM‐2 is a novel taxane derivative. The present paper describes an investigation of the physicochemical properties and degradation kinetics of TM‐2 to determine the use of lipid emulsions as suitable drug carriers, and also to develop and evaluate a highly stable and sterile optimal formulation of a TM‐2 lipid emulsion (TLE). The properties of TM‐2, such as its solubility in water and oils, partition coefficient, stability in aqueous solutions and oils, indicated that TM‐2 was an excellent candidate for o/w emulsions. A preformulation study indicated that degradation of TM‐2 took place mostly in water compared with that in oils. Moreover, the influence of pH, temperature, and ionic strength on the stability of TM‐2 in water solutions was assessed. An emulsion formulation of TM‐2 which was stable enough to undergo sterilization was successfully developed. Using the Arrhenius equation, the shelf‐life of TM‐2 in lipid emulsion was estimated to be 2665.5 days at 4°C, which was much longer than that of 113.0 days in aqueous solution. Thus, TLE was clearly superior to the TM‐2 aqueous solution in terms of stability. Short‐term stability investigations showed that the TLE was stable for a period of 3 months at 4 and 25°C.Practical applications: The application of taxanes in anti‐cancer field is limited by de novo refractoriness or acquired resistance, which are common drawbacks to most anti‐cancer cytotoxic agents. TM‐2 is a novel semi‐synthetic taxane derivative, which can overcome multidrug resistance. Some non‐ionic surfactants, such as Cremophor EL and Tween 80 (polysorbate 80), usually used in the commercial formulations of the taxanes to improve their poor water‐solubility, have exhibited serious adverse effects including hypersensitivity reactions and peripheral neuropathy in human. In this study, preformulation study showed that TM‐2 exhibited excellent solubility in oils and, thus, the problems associated with the poor solubility of TM‐2 were overcome by loading TM‐2 into the interior oil phase of o/w lipid emulsions. According to the degradation kinetics results, the shelf lives (T0.9) of TM‐2 lipid emulsions at 25 and 4°C were dramatically prolonged.
- 8 January 2014
- Published by Taylor & Francis in Drug Delivery
- Vol. 21 (6) , 495-500
Influence of potential inhalation carriers on stability of thymopentin in rat bronchoalveolar lavage fluid
In the present study, the stability of thymopentin (TP5) in bronchoalveolar lavage fluid (BALF) in presence of potential excipients in inhalation formulation was investigated. The content of TP5 was determined using HPLC method. Commonly used bulking agent, dispersibility enhancers and absorption enhancers in inhalation were investigated with respect to the stability of TP5 in BALF. Finally, the stability of TP5 in two inhalation formulations based on the screening experiments was tested in BALF. The results showed that TP5 alone degraded very rapidly in BALF and zero-order enzymatic reaction with a half-life of t0.5 = 49.20 min was observed using 10 times diluted BALF. Among the amino acids examined, leucine and phenylalanine effectively inhibited the enzymolysis of TP5 with prolonged half-life of 112.7 min and 136.2 min, respectively. Nevertheless, slight but insignificant inhibition effect was witnessed for tyrosine, aspartic acid, and lysine; and negligible prevention on the degradation process of TP5 were found for lactose and mannitol. Regarding chitosan, irrespective with molecular weight, the formation of chitosan-TP5 complex improved the stability of TP5 with prolonged t0.5 by 1.8 times. However, along with the improved stability of TP5 in spray-dried chitosan microspheres, the content of TP5 in formulations was reduced to about 75% during preparation process. Thus, leucine was proved to be a prior candidate for inhalation formulation of TP5. Consequently, the results indicate the potential of leucine as carrier for pulmonary delivery of TP5 serving as both stabilizer and dispersibility enhancer.
- 8 January 2014
- Published by Taylor & Francis in Drug Delivery
- Vol. 21 (6) , 495-500
Influence of potential inhalation carriers on stability of thymopentin in rat bronchoalveolar lavage fluid
In the present study, the stability of thymopentin (TP5) in bronchoalveolar lavage fluid (BALF) in presence of potential excipients in inhalation formulation was investigated. The content of TP5 was determined using HPLC method. Commonly used bulking agent, dispersibility enhancers and absorption enhancers in inhalation were investigated with respect to the stability of TP5 in BALF. Finally, the stability of TP5 in two inhalation formulations based on the screening experiments was tested in BALF. The results showed that TP5 alone degraded very rapidly in BALF and zero-order enzymatic reaction with a half-life of t0.5 = 49.20 min was observed using 10 times diluted BALF. Among the amino acids examined, leucine and phenylalanine effectively inhibited the enzymolysis of TP5 with prolonged half-life of 112.7 min and 136.2 min, respectively. Nevertheless, slight but insignificant inhibition effect was witnessed for tyrosine, aspartic acid, and lysine; and negligible prevention on the degradation process of TP5 were found for lactose and mannitol. Regarding chitosan, irrespective with molecular weight, the formation of chitosan-TP5 complex improved the stability of TP5 with prolonged t0.5 by 1.8 times. However, along with the improved stability of TP5 in spray-dried chitosan microspheres, the content of TP5 in formulations was reduced to about 75% during preparation process. Thus, leucine was proved to be a prior candidate for inhalation formulation of TP5. Consequently, the results indicate the potential of leucine as carrier for pulmonary delivery of TP5 serving as both stabilizer and dispersibility enhancer.
- 4 August 2011
- Published by Taylor & Francis in Drug Delivery
- Vol. 18 (8) , 578-585
Evaluation of submicron emulsion as vehicles for rapid-onset intranasal delivery and improvement in brain targeting of zolmitriptan
This study was to evaluate submicron emulsion as a drug carrier for intranasal delivery of zolmitriptan (ZT). Since the drug distribution in submicron emulsion might influence the nasal absorption, two different formulations separately incorporating the drug in oily phase (ZTSE-1) and aqueous phase (ZTSE-2) were assessed. To find the better formulation for rapid-onset intranasal delivery and improvement in brain targeting of ZT, the in vivo nasal absorption of these two formulations was evaluated. The blood and cerebrospinalfluid (CSF) pharmacokinetics of ZTSE-1, ZTSE-2 and ZT solution (ZTS) were evaluated after intranasal administered to anesthetized Wistar rats. The results demonstrated that ZT from ZTSE-1 and ZTSE-2 had better brain targeting efficiency than the ZTS. In plasma and CSF, the ZTSE-2 reached peak concentration much faster than ZTSE-1 and ZTS. The ZTSE-2 also presented significantly higher initial ZT levels in CSF compared with the ZTSE-1 and ZTS. The results indicated that incorporation of ZT in the aqueous phase of submicron emulsion was effective for rapid intranasal delivery of drug to blood and brain, which would offer patients the benefits of rapid relief from migraine.
- 4 August 2011
- Published by Taylor & Francis in Drug Delivery
- Vol. 18 (8) , 578-585
Evaluation of submicron emulsion as vehicles for rapid-onset intranasal delivery and improvement in brain targeting of zolmitriptan
This study was to evaluate submicron emulsion as a drug carrier for intranasal delivery of zolmitriptan (ZT). Since the drug distribution in submicron emulsion might influence the nasal absorption, two different formulations separately incorporating the drug in oily phase (ZTSE-1) and aqueous phase (ZTSE-2) were assessed. To find the better formulation for rapid-onset intranasal delivery and improvement in brain targeting of ZT, the in vivo nasal absorption of these two formulations was evaluated. The blood and cerebrospinalfluid (CSF) pharmacokinetics of ZTSE-1, ZTSE-2 and ZT solution (ZTS) were evaluated after intranasal administered to anesthetized Wistar rats. The results demonstrated that ZT from ZTSE-1 and ZTSE-2 had better brain targeting efficiency than the ZTS. In plasma and CSF, the ZTSE-2 reached peak concentration much faster than ZTSE-1 and ZTS. The ZTSE-2 also presented significantly higher initial ZT levels in CSF compared with the ZTSE-1 and ZTS. The results indicated that incorporation of ZT in the aqueous phase of submicron emulsion was effective for rapid intranasal delivery of drug to blood and brain, which would offer patients the benefits of rapid relief from migraine.